Building on Novartis' longstanding strength in Neuroscience plus the recent explosion of scientific knowledge and technology catalyzing the field, teams are tackling diseases that seemed intractable just five years ago. The time is finally ripe for pathways-based rational drug discovery in many neurological indications. Novartis is hiring 70 associates by 2014 and 30 more during the next few years at our Cambridge, MA global research headquarters to help patients with neuropsychiatric and neurodegenerative diseases.

We are taking advantage of new tools, including induced pluripotent stem cells and optogenetics, and of academic collaborations to sift through genetic clues, build disease models and deepen our understanding of neural circuits. Our research in Neuroscience aims to leverage the latest advances in human genetics to probe the underlying pathophysiology of diseases, such as Autism, Schizophrenia and Bipolar disorder, as well as, Parkinson's disease, Alzheimer's disease and Frontotemporal Dementias.

Learn more from Ricardo Dolmetsch, Ph.D., NIBR's new Global Head of Neuroscience.




Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons.
Krey JF, Paşca SP, Shcheglovitov A, Yazawa M, Schwemberger R, Rasmusson R, Dolmetsch RE.
Nat Neurosci. 2013 Feb;16(2):201-9. doi: 10.1038/nn.3307. Epub 2013 Jan 13.
PMID: 23313911 [PubMed - indexed for MEDLINE]

Genome-wide association analysis identifies 13 new risk loci for schizophrenia.
Ripke S, et al,
Nat Genet. 2013 Aug 25. doi: 10.1038/ng.2742. [Epub ahead of print]
PMID: 23974872 [PubMed - as supplied by publisher]